Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Employees - 159, CEO - Dr. Robert Ang M.B.A., M.D., MBBS, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -9.12, Piotroski Score(max is 10): 1, Working Capital: $48120000, Total Assets: $109312000, Retained Earnings: $-489480000, EBIT: -123050000, Total Liabilities: $43243000, Revenue: $0

- Current Price $ - Analyst Target Price $